Anuwat LimsuwanVina ChurdboonchartRonald B. MossWorachart SirawarapornReungpung SutthentBuranaj SmutharaksDavid GliddenRichard TraugerGeorgia TheofanDennis CarloMahidol UniversityOrchestra Therapeutics IncHarvard School of Public Health2018-07-042018-07-041998-01-01Vaccine. Vol.16, No.2-3 (1998), 142-1490264410X2-s2.0-0031986269https://repository.li.mahidol.ac.th/handle/20.500.14594/18327The safety and immunogenicity of REMUNE(TM), an HIv-specific immune based therapy for HIV infection, was evaluated in a cohort of 30 HIV infected subjects in Thailand. This therapy utilizes a gp120 depleted inactivated virus (HZ321), which exhibits a high degree of conservation with the core antigens of both type B' and E strains of HIV the predominant Thailand isolates. The treatment was well tolerated, with no serious adverse events reported over the course of the 4-month trial. Treatment in which four doses were administered with REMUNE(TM) appeared to boost HIV-specific immune responses, with approximately 75% of the treated subjects demonstrating an increase in either the repertoire or the intensity of the serological response to HIV as measured by Western blot. CD4%, viral load, and weight remained stable over the course of the 4-month study relative to baseline values. Viral subtyping of this cohort revealed a predominance of type 'E'. These data suggest that REMUNE(TM) is safe and immunogenic in seropositive Thai subjects and supports further study of the therapeutic potential of REMUNE(TM) to treat HIV-1 infection.Mahidol UniversityBiochemistry, Genetics and Molecular BiologyImmunology and MicrobiologyMedicineVeterinaryArticleSCOPUS10.1016/S0264-410X(97)88327-2